22ND CENTURY GROUP INC (XXII) Fundamental Analysis & Valuation

NASDAQ:XXII • US90137F6088

Current stock price

1.69 USD
-0.36 (-17.56%)
Last:

This XXII fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. XXII Profitability Analysis

1.1 Basic Checks

  • In the past year XXII has reported negative net income.
  • In the past year XXII has reported a negative cash flow from operations.
  • In the past 5 years XXII always reported negative net income.
  • XXII had a negative operating cash flow in each of the past 5 years.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -36.02%, XXII is doing worse than 75.00% of the companies in the same industry.
  • XXII has a Return On Equity (-52.63%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -36.02%
ROE -52.63%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for XXII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. XXII Health Analysis

2.1 Basic Checks

  • XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500 1K 1.5K 2K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -20.85, we must say that XXII is in the distress zone and has some risk of bankruptcy.
  • XXII has a worse Altman-Z score (-20.85) than 75.00% of its industry peers.
  • XXII has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.03, XXII belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -20.85
ROIC/WACCN/A
WACC7.52%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • XXII has a Current Ratio of 2.42. This indicates that XXII is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.42, XXII is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
  • XXII has a Quick Ratio of 1.83. This is a normal value and indicates that XXII is financially healthy and should not expect problems in meeting its short term obligations.
  • XXII's Quick ratio of 1.83 is fine compared to the rest of the industry. XXII outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 1.83
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. XXII Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.39% over the past year.
  • The Revenue for XXII has decreased by -27.87% in the past year. This is quite bad
  • Measured over the past years, XXII shows a decrease in Revenue. The Revenue has been decreasing by -8.95% on average per year.
EPS 1Y (TTM)99.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.74%
Revenue 1Y (TTM)-27.87%
Revenue growth 3Y-24.27%
Revenue growth 5Y-8.95%
Sales Q2Q%-12.04%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year79.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 -1M -2M -3M -4M -5M

More info and screens

Find the best growth stocksShow best growing peers

0

4. XXII Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XXII. In the last year negative earnings were reported.
  • Also next year XXII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600 -800 -1K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XXII Dividend Analysis

5.1 Amount

  • XXII does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XXII Fundamentals: All Metrics, Ratios and Statistics

22ND CENTURY GROUP INC

NASDAQ:XXII (4/23/2026, 2:53:02 PM)

1.69

-0.36 (-17.56%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners9.09%
Inst Owner Change200%
Ins Owners2.81%
Ins Owner Change1.43%
Market Cap1.22M
Revenue(TTM)17.59M
Net Income(TTM)-9.73M
Analysts82.86
Price Target137.7 (8047.93%)
Short Float %17.18%
Short Ratio2.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.22%
Min EPS beat(2)-42.36%
Max EPS beat(2)98.8%
EPS beat(4)1
Avg EPS beat(4)-60.04%
Min EPS beat(4)-181.72%
Max EPS beat(4)98.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-10.9%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-6.37%
Revenue beat(4)1
Avg Revenue beat(4)-5.99%
Min Revenue beat(4)-26.42%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-22.27%
Revenue beat(12)2
Avg Revenue beat(12)-18.16%
Revenue beat(16)3
Avg Revenue beat(16)-19.41%
PT rev (1m)0%
PT rev (3m)1400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1400%
EPS NY rev (1m)0%
EPS NY rev (3m)-1400%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-1082.64
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-11.94
FCFYN/A
OCF(TTM)-10.73
OCFYN/A
SpS24.43
BVpS25.68
TBVpS17.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -36.02%
ROE -52.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.94%
Cap/Sales 4.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 1.83
Altman-Z -20.85
F-Score4
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)84.72%
Cap/Depr(5y)98.99%
Cap/Sales(3y)7.69%
Cap/Sales(5y)7.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.74%
EPS Next Y99.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.87%
Revenue growth 3Y-24.27%
Revenue growth 5Y-8.95%
Sales Q2Q%-12.04%
Revenue Next Year79.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year123.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.16%
OCF growth 3YN/A
OCF growth 5YN/A

22ND CENTURY GROUP INC / XXII Fundamental Analysis FAQ

What is the fundamental rating for XXII stock?

ChartMill assigns a fundamental rating of 1 / 10 to XXII.


What is the valuation status of 22ND CENTURY GROUP INC (XXII) stock?

ChartMill assigns a valuation rating of 0 / 10 to 22ND CENTURY GROUP INC (XXII). This can be considered as Overvalued.


What is the profitability of XXII stock?

22ND CENTURY GROUP INC (XXII) has a profitability rating of 0 / 10.


What is the financial health of 22ND CENTURY GROUP INC (XXII) stock?

The financial health rating of 22ND CENTURY GROUP INC (XXII) is 4 / 10.